Pharmacy Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab
Bristol Myers-Squibb Company, 06/01/09

Bristol-Myers Squibb Company and Medarex, Inc. announced updated survival results from follow-up extensions of three Phase 2 ipilimumab studies of patients with advanced metastatic melanoma. The two-year survival rate ranged from 29.8 to 41.8 percent in patients who received ipilimumab. Results of the survival data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology in Orlando, FL., May – June 2009.

<< Previous
Maintenance treatment with Avastin and Tarceva in combination...

Next >>
Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for...